Cargando…
Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C
The advent of direct-acting antiviral drugs (DAAs) was a breakthrough in the treatment of patients with chronic hepatitis C, yet high viral replication errors can lead to the development of resistance associated variants (RAVs). Thus, assessment of RAV in infected patients is necessary to monitor tr...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139387/ https://www.ncbi.nlm.nih.gov/pubmed/35626210 http://dx.doi.org/10.3390/diagnostics12051054 |
_version_ | 1784714847827525632 |
---|---|
author | Valutite, Diana Ostankova, Yulia Semenov, Alexandr Lyalina, Liudmila Totolian, Areg |
author_facet | Valutite, Diana Ostankova, Yulia Semenov, Alexandr Lyalina, Liudmila Totolian, Areg |
author_sort | Valutite, Diana |
collection | PubMed |
description | The advent of direct-acting antiviral drugs (DAAs) was a breakthrough in the treatment of patients with chronic hepatitis C, yet high viral replication errors can lead to the development of resistance associated variants (RAVs). Thus, assessment of RAV in infected patients is necessary to monitor treatment effectiveness. The aim of our study was to investigate the presence of primary resistance mutations in the NS3 and NS5 regions of HCV in treatment-naive patients. Samples were taken from 42 patients with HCV who had not previously received DAA treatment. In the present study, we used the method for determining drug resistance mutations based on direct sequencing of the NS3, NS5A, and NS5B genes developed by the Saint Petersburg Pasteur Institute. Primary mutations associated with resistance were detected in 5 patients (12%). According to the Geno2pheno [hcv] 0.92 database, nucleotide substitutions were identified in various viral genes conferring resistance or decreased sensitivity to the respective inhibitors. This study has shown different mutations in the analyzed genes in patients with HCV who had not previously received DAA treatment. These mutations may increase the likelihood of treatment failure in the future. |
format | Online Article Text |
id | pubmed-9139387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91393872022-05-28 Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C Valutite, Diana Ostankova, Yulia Semenov, Alexandr Lyalina, Liudmila Totolian, Areg Diagnostics (Basel) Article The advent of direct-acting antiviral drugs (DAAs) was a breakthrough in the treatment of patients with chronic hepatitis C, yet high viral replication errors can lead to the development of resistance associated variants (RAVs). Thus, assessment of RAV in infected patients is necessary to monitor treatment effectiveness. The aim of our study was to investigate the presence of primary resistance mutations in the NS3 and NS5 regions of HCV in treatment-naive patients. Samples were taken from 42 patients with HCV who had not previously received DAA treatment. In the present study, we used the method for determining drug resistance mutations based on direct sequencing of the NS3, NS5A, and NS5B genes developed by the Saint Petersburg Pasteur Institute. Primary mutations associated with resistance were detected in 5 patients (12%). According to the Geno2pheno [hcv] 0.92 database, nucleotide substitutions were identified in various viral genes conferring resistance or decreased sensitivity to the respective inhibitors. This study has shown different mutations in the analyzed genes in patients with HCV who had not previously received DAA treatment. These mutations may increase the likelihood of treatment failure in the future. MDPI 2022-04-22 /pmc/articles/PMC9139387/ /pubmed/35626210 http://dx.doi.org/10.3390/diagnostics12051054 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Valutite, Diana Ostankova, Yulia Semenov, Alexandr Lyalina, Liudmila Totolian, Areg Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C |
title | Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C |
title_full | Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C |
title_fullStr | Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C |
title_full_unstemmed | Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C |
title_short | Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C |
title_sort | distribution of primary resistance mutations in saint petersburg in patients with chronic hepatitis c |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139387/ https://www.ncbi.nlm.nih.gov/pubmed/35626210 http://dx.doi.org/10.3390/diagnostics12051054 |
work_keys_str_mv | AT valutitediana distributionofprimaryresistancemutationsinsaintpetersburginpatientswithchronichepatitisc AT ostankovayulia distributionofprimaryresistancemutationsinsaintpetersburginpatientswithchronichepatitisc AT semenovalexandr distributionofprimaryresistancemutationsinsaintpetersburginpatientswithchronichepatitisc AT lyalinaliudmila distributionofprimaryresistancemutationsinsaintpetersburginpatientswithchronichepatitisc AT totolianareg distributionofprimaryresistancemutationsinsaintpetersburginpatientswithchronichepatitisc |